Private Management Group Inc. Acquires 225,420 Shares of Organon & Co. (NYSE:OGN)

Private Management Group Inc. boosted its holdings in Organon & Co. (NYSE:OGN) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,119,288 shares of the company’s stock after purchasing an additional 225,420 shares during the quarter. Organon & Co. comprises 1.1% of Private Management Group Inc.’s holdings, making the stock its 23rd largest holding. Private Management Group Inc.’s holdings in Organon & Co. were worth $31,620,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Sippican Capital Advisors increased its stake in shares of Organon & Co. by 4.3% in the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after acquiring an additional 627 shares in the last quarter. Commerce Bank increased its stake in Organon & Co. by 5.5% in the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after purchasing an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after purchasing an additional 672 shares during the period. Graypoint LLC boosted its position in shares of Organon & Co. by 6.2% during the 3rd quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after purchasing an additional 853 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Organon & Co. by 19.5% during the 3rd quarter. KBC Group NV now owns 7,744 shares of the company’s stock worth $148,000 after purchasing an additional 1,263 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $21.33.

Organon & Co. Trading Up 2.5 %

NYSE:OGN opened at $15.32 on Thursday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a market cap of $3.94 billion, a PE ratio of 3.04, a PEG ratio of 0.87 and a beta of 0.76. The firm has a 50-day moving average of $15.41 and a 200-day moving average of $17.79.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.